

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-505

CHEMISTRY REVIEW(S)

NDA 21-505

Keppra (levetiracetam) Oral Solution 100 mg/mL

UCB Pharma, Inc.

Thomas A. Broadbent, Ph.D.
Division of Neuropharmacological Drug Products

Table of Contents

Chemistry Review Data Sheet	3
The Executive Summary	6
I. Recommendations	6
A. Recommendation and Conclusion on Approvability	6
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	6
II. Summary of Chemistry Assessments	6
A. Description of the Drug Product and Drug Substance	6
B. Description of How the Drug Product is Intended to be Used	6
C. Basis for Approvability or Not-Approval Recommendation	6
III. Administrative	7
A. Reviewer's Signature	7
B. Endorsement Block	7
C. CC Block.....	7
Chemistry Assessment	8
V. METHODS VALIDATION	8
VI. LABELING	8

Chemistry NDA Review Data Sheet

1. NDA # 21-505

2. REVIEW #: 2


3. REVIEW DATE: 09-JUL-2003

4. REVIEWER: Thomas A. Broadbent, Ph.D.

5. PREVIOUS DOCUMENTS

Previous DocumentsDocument Date

T-con (5 total) (01-AUG-2002) (08-OCT-2002) (14-MAR-2003) (10-APR-2003) (09-JUL-03)
CMC Review # 1 14-APR-03



6. SUBMISSIONS BEING REVIEWED:

Submissions ReviewedDocument Date

Amendment of original NDA

21-MAY-2003

7. NAME & ADDRESS OF APPLICANT:

Name: UCB Pharma, Inc.

Address: 1950 Lake Park Drive, Smyrna, GA 30080

Representative: Patricia Fritz

Contact for CMC Issues:

Mary Alonso

Telephone: (770) 437-5554

Telephone:

(770) 970-8580

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: Keppra® Oral Solution

b) Non-Proprietary Name (USAN): levetiracetam

c) Code Name / # ucb L059

d) Chem. Type/Submission Priority

Chem. Type = 3

Submission Priority = S

9. LEGAL BASIS FOR SUBMISSION: N/A

10. PHARMACOLOGICAL CATEGORY: Adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy

11. DOSAGE FORM: Oral Solution

12. STRENGTH / POTENCY: 100 mg / mL

13. ROUTE OF ADMINISTRATION: oral

14. Rx / OTC DISPENSED: XXX Rx ___ OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM)

Not Applicable

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Chemical Name: (-)-(S)- α -ethyl-2-oxo-1-pyrrolidineacetamideFormula: $C_8H_{14}N_2O_2$

Formula Weight: 170.21

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE (1)	STATUS (2)	DATE REVIEW COMPLETED	COMMENTS
1	2			1	Adequate	7/26/02	
1	3			4	N/A	--	Information in NDA
1	3			3	Adequate	8/12/99	
1	3			3	Adequate	7/30/01	
1	3			4	N/A	--	Information in NDA
1	3			4	N/A	--	Information in NDA
1	3			3	Adequate	11/05/98	
1	3			3	Adequate	3/08/99	
1	3			3	Adequate	4/30/02	
1	3			3	Adequate	2/14/03	
1	3			4	N/A	--	Information in DMF & NDA
1	3			4	N/A	--	Information in DMF
1	3			3	Adequate	2/23/01	
1	3			4	N/A	--	Information in NDA
1	3			3	Adequate	9/15/00	
1	3			3	Adequate	9/27/00	
1	3			3	Adequate	3/22/01	

⁽¹⁾ Action codes for DMF Table:

1 – DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2 – Type 1 DMF

3 – Reviewed previously and no revision since last review

4 – Sufficient information in application

5 – Authority to reference not granted

6 – DMF not available

7 – Other (explain under "Comments")

⁽²⁾ Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	45,151	Development of Keppra Tablets & Oral Solution
NDA	21-035 (AP 30-NOV-99)	Levetiracetam DS & Keppra Tablets

18. STATUS:

CONSULTS / CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biostatistics	N/A	--	--
EES	Acceptable	19 December 2002	Shirnette Ferguson
Pharm/Tox	Approval	14 April 2003	Ed Fisher
Biopharm	Approval	2 April 2003	Kofi Kumi
LNC	N/A	--	--
Methods Validation	Pending	Pending	Thomas Broadbent
ODS/DSRCS	Comments to DNPDP	9 April 2003	Janine Best
EA	Adequate	31 October 2002	Florian Zielinsky
Microbiology	Approval	17 January 2003	Vinayak Pawar
DMETS	Comments to DNPDP	2 April 2003	Marci Lee

APPEARS THIS WAY
ON ORIGINAL

Chemistry Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

APPROVAL of NDA 21-505 is recommended from a CMC perspective. The sponsor has revised the NDA to include a recommendation for an additional in-process control _____ and a commitment to update European Pharmacopoeia methods included in the NDA by prior approval supplements. Two changes in labeling concerning CMC have been effected in the current draft of insert labeling; one is according to recommendation and the other is a deleted listing of a coloring agent for Kepra Tablets (adequate for NDA 21-035).

B. Recommendation on Phase 4 (Post-Marketing) Commitments and Risk Management Steps

No phase 4 commitments

II. Summary of Chemistry Assessments

A. Description of the Drug Product and Drug Substance

Kepra® Oral Solution is a grape-flavored, alcohol-free and sugar-free aqueous solution. The solution is non-sterile, with microbiological limits for total viable count (NMT _____ and *Salmonella* and *E. coli* (negative). Methyl paraben and propyl paraben are ingredients as preservatives. The pH range of the solution is specified as _____. The solution API concentration is 100 mg/mL or 1500 mg per 15 mL, the typical dose.

_____ The commercial product is packaged in 16 oz glass and HDPE bottles (labeled amount 475 mL). The solution can become discolored in light, but the packaging provides adequate protection from light.

Levetiracetam (USAN, INN & BAN) is a white to off-white crystalline powder with a faint odor. Description of the chemistry, manufacturing and control of the drug substance (ucb L059) is provided in NDA 21-035, Kepra Tablets. It is very soluble in water; the limit of solubility is approximately 104 g per 100 mL of water. Particle size and crystal aggregation are not relevant to this application because the product is provided as a solution. (Differences in these physical characteristics have been observed for different synthetic routes.) The retest period of the bulk drug substance is _____. The _____ impurities of the drug product are _____.

B. Description of How the Drug Product is Intended to be Used

Kepra is indicated as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The recommended initial treatment is 500 mg *BID*. Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg.

Expiration dating: 24 months is proposed. The reviewer concurs.

Recommended storage condition: 25°C (77°F); excursions permitted to 15-30° (59-86°F)

[See USP Controlled Room Temperature]

C. Basis for Approvability or Not-Approval Recommendation

Approval was recommended in CMC Review # 1. The CMC provisions of the amended submission are according to recommendations or are minor in nature. They do not change the recommendation for approval.

III. Administrative

A. Reviewer's Signature

Electronic signature in Division File System

B. Endorsement Block

See Division File System

C. CC Block

Thomas Broadbent, CMC Reviewer, HFD-120

Maryla Guzewska, Neurology CMC Team Leader, HFD-120

Melina Griffis, Project Manager, HFD-120

1 Page(s) Withheld

,

• This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/

Thomas Broadbent
7/14/03 02:10:32 PM
CHEMIST

Maryla Guzewska
7/14/03 02:13:04 PM
CHEMIST



NDA 21-505

Keppra (levetiracetam) Oral Solution 100 mg/mL

UCB Pharma, Inc.

Thomas A. Broadbent, Ph.D.
Division of Neuropharmacological Drug Products

Table of Contents

Chemistry Review Data Sheet	4
The Executive Summary	7
I. Recommendations	7
A. Recommendation and Conclusion on Approvability	7
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	7
II. Summary of Chemistry Assessments	7
A. Description of the Drug Product and Drug Substance	7
B. Description of How the Drug Product is Intended to be Used	7
C. Basis for Approvability or Not-Approval Recommendation	7
III. Administrative	8
A. Reviewer's Signature	8
B. Endorsement Block	8
C. CC Block	8
Chemistry Assessment	9
A. DRUG SUBSTANCE	9
B. DRUG PRODUCT	9
1. Components/Composition	9
2. Specifications & Methods for Drug Product Ingredients	10
a. Active Ingredient	10
b. Inactive Ingredients	11
3. Manufacturer	15
4. Methods of Manufacturing and Packaging	15
a. Production Operations	15
b. In-Process Controls & Tests	17
c. Reprocessing Operations	17

5. Regulatory Specifications and Methods for Drug Product.....	18
a. Sampling Procedures	18
b. Regulatory Specifications and Methods	18
6. Container/Closure System.....	24
7. Microbiology	28
8. Drug Product Stability	28
III. INVESTIGATIONAL FORMULATIONS	30
IV. ENVIRONMENTAL ASSESSMENT	30
V. METHODS VALIDATION.....	31
VI. LABELING	31
VII. ESTABLISHMENT INSPECTION	33
VIII. DEFICIENCY LETTER	36

<u>Index of Review Tables</u>	<u>Page</u>
Table 1 - Batch Formula - Keppra® Oral Solution	9
Table 2 - Levetiracetam Specifications - API for Keppra® Formulations.....	10
Table 3 - Certificate of Quality - Levetiracetam batch 55606	11
Table 4 - UCB Specifications for 	12
Table 5 - 21 CFR 184.1408 Specifications for 	13
Table 6 - UCB / Ph. Eur. Specifications for Potassium Acesulfame.....	13
Table 7 - 21 CFR 172.800 Specifications for Acesulfame Potassium.....	14
Table 8 - Product Specifications for Grape Flavor 	14
Table 9 - Manufacturing In-process Controls - Bulk Solution	17
Table 10 - Manufacturing In-process Controls - Filling	17
Table 11 - Sampling for Release Testing of Keppra® Oral Solution.....	18
Table 12 - Specifications for Keppra® Oral Solution (100 mg/mL levetiracetam).....	18
Table 13 - Purity Specifications for Levetiracetam DS	21
Table 14 - Purity Specifications Keppra Tablets.....	21
Table 15 - DP Stability Results at 25°C for Latest Interval 	21
Table 16 - CoA Batch #UKS0001-ST	22
Table 17 - CoA Batch #UKS0101-ST	23
Table 18 - CoA Batch #UKS0102-ST	23
Table 19 - Description of Container/Closure System - Glass Bottles.....	24
Table 20 - Description of Container/Closure System - HDPE Bottles.....	24
Table 21 - Keppra Oral Solution Stability Protocol Conditions & Test Intervals.....	29

Chemistry NDA Review Data Sheet

1. NDA # 21-505

2. REVIEW #: 1

3. REVIEW DATE: 14-APR-2003

4. REVIEWER: Thomas A. Broadbent, Ph.D.


5. PREVIOUS DOCUMENTS

Previous Documents

T-con (4 total)

Document Date

(01-AUG-2002) (08-OCT-2002) (14-MAR-2003) (10-APR-2003)



6. SUBMISSIONS BEING REVIEWED:

Submissions ReviewedDocument Date

Original

20-JUN-2002

Amendment

23-OCT-2002

Amendment

09-APR-2003

7. NAME & ADDRESS OF APPLICANT:

Name: UCB Pharma, Inc.

Address: 1950 Lake Park Drive, Smyrna, GA 30080

Representative: Patricia Fritz

Contact for CMC Issues:

Mary Alonso

Telephone: (770) 437-5554

Telephone:

(770) 970-8580

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: Keppra® Oral Solution

b) Non-Proprietary Name (USAN): levetiracetam

c) Code Name / # ucb L059

d) Chem. Type/Submission Priority

Chem. Type = 3

Submission Priority = S

9. LEGAL BASIS FOR SUBMISSION:

Section 505(b) of the Federal Food, Drug, and Cosmetic Act

10. PHARMACOLOGICAL CATEGORY: Adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy

11. DOSAGE FORM: Oral Solution

12. STRENGTH / POTENCY: 100 mg / mL

13. ROUTE OF ADMINISTRATION: oral

14. Rx / OTC DISPENSED: XXX Rx OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM)

Not Applicable

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Chemical Name: (-)-(S)- α -ethyl-2-oxo-1-pyrrolidineacetamide

Formula: $C_8H_{14}N_2O_2$

Formula Weight: 170.21

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE (1)	STATUS (2)	DATE REVIEW COMPLETED	COMMENTS
1	2			1	Adequate	7/26/02	
2	3			4	N/A	--	Information in NDA
3	3			3	Adequate	8/12/99	
4	3			3	Adequate	7/30/01	
5	3			4	N/A	--	Information in NDA
6	3			4	N/A	--	Information in NDA
7	3			3	Adequate	11/05/98	
8	3			3	Adequate	3/08/99	
9	3			3	Adequate	4/30/02	
10	3			3	Adequate	2/14/03	
11	3			4	N/A	--	Information in DMF <u> </u> & NDA
12	3			4	N/A	--	Information in DMF <u> </u>
13	3			3	Adequate	2/23/01	
14	3			4	N/A	--	Information in NDA
15	3			3	Adequate	9/15/00	
16	3			3	Adequate	9/27/00	
17	3			3	Adequate	3/22/01	

(1) Action codes for DMF Table:

1 – DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2 – Type 1 DMF

3 – Reviewed previously and no revision since last review

4 – Sufficient information in application

5 – Authority to reference not granted

6 – DMF not available

7 – Other (explain under "Comments")

(2) Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)



B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	45,151	Development of Keppra Tablets & Oral Solution
NDA	21-035 (AP 30-NOV-99)	Levetiracetam DS & Keppra Tablets

18. STATUS:

CONSULTS / CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biostatistics	N/A	--	--
EES	Acceptable	19 December 2002	Shirnette Ferguson
Pharm/Tox	Pending	Pending	Ed Fisher
Biopharm	Approval	2 April 2003	Kofi Kumi
LNC	N/A	--	--
Methods Validation	Pending	Pending	Thomas Broadbent
ODS/DSRCS	Comments to DNPDP	9 April 2003	Janine Best
EA	Adequate	31 October 2002	Florian Zielinsky
Microbiology	Approval	17 January 2003	Vinayak Pawar
DMETS	Comments to DNPDP	2 April 2003	Marci Lee

APPEARS THIS WAY
ON ORIGINAL

Chemistry Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

APPROVAL of NDA 21-505 is recommended from a CMC perspective.

The action letter should include a reminder of the sponsor's commitments.

1. UCB will provide updates for *European Pharmacopoeia* methods included in ingredient and product specifications by CBE supplements.
2. In-process range limits will be established for the _____
3. A methods validation package will be provided for the ID, drug assay & related substance HPLC method.

B. Recommendation on Phase 4 (Post-Marketing) Commitments and Risk Management Steps

No phase 4 commitments

II. Summary of Chemistry Assessments

A. Description of the Drug Product and Drug Substance

Keppra® Oral Solution is a grape-flavored, alcohol-free and sugar-free aqueous solution. The solution is non-sterile, with microbiological limits for total viable count (NMT _____) and *Salmonella* and *E. coli* (negative). Methyl paraben and propyl paraben are ingredients as preservatives. The pH range of the solution is specified as _____. The solution API concentration is 100 mg/mL or 1500 mg per 15 mL, the typical dose. _____

_____ The commercial product is packaged in 16 oz glass and HDPE bottles (labeled amount 475 mL). The solution can become discolored in light, but the packaging provides adequate protection from light.

Levetiracetam (USAN, INN & BAN) is a white to off-white crystalline powder with a faint odor. Description of the chemistry, manufacturing and control of the drug substance (ucb L059) is provided in NDA 21-035, Keppra Tablets. It is very soluble in water; the limit of solubility is approximately 104 g per 100 mL of water. Particle size and crystal aggregation are not relevant to this application because the product is provided as a solution. (Differences in these physical characteristics have been observed for different synthetic routes.) The retest period of the bulk drug substance is _____. The _____ impurities of the drug product are _____

B. Description of How the Drug Product is Intended to be Used

Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The recommended initial treatment is 500 mg *BID*. Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg.


Expiration dating: 24 months is proposed. The reviewer concurs.

Recommended storage condition: 25°C (77°F); excursions permitted to 15-30° (59-86°F)

[See USP Controlled Room Temperature]

C. Basis for Approvability or Not-Approval Recommendation

CMC provisions warrant approval. The applicant has adequately documented the composition of the product, control of the ingredients, the manufacturing process, and the release of the product. Stability data are adequate to support the proposed expiration period of 24 months. Establishment evaluation has been completed and an overall acceptable compliance recommendation was received (19 December 2002).



III. Administrative

A. Reviewer's Signature

Electronic signature in Division File System

B. Endorsement Block

See Division File System

C. CC Block

Thomas Broadbent, CMC Reviewer, HFD-120

Maryla Guzewska, Neurology CMC Team Leader, HFD-120

Jackie Ware, Project Manager, HFD-120

Melina Griffis, Project Manager, HFD-120

29 Page(s) Withheld

,

This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/

Thomas Broadbent
4/14/03 05:47:05 PM
CHEMIST

Maryla Guzewska
4/15/03 07:39:29 AM
CHEMIST